Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
boston blog main
boston top stories
clinical trials
life sciences
national blog main
national top stories
sanofi
3
×
biotech
deals
inclisiran
new york
new york blog main
new york top stories
pcsk9
regeneron pharmaceuticals
san francisco blog main
san francisco top stories
alirocumab
alnylam pharmaceuticals
cancer
cancer drugs
cholesterol
cobimetinib
data
evolocumab
fda
investing
ipo
ldl
mark timney
mt sinai hospital
novartis
pcsk9 inhibitors
peter wijngaard
praluent
prashant vaishnava
repatha
revolution medicines
rna interference
What
drug
3
×
medicines
3
×
cholesterol
medco
aces
acquire
agreed
announced
big
billion
brings
cancer
cash
ceo
company
compound
deal
despite
family
fda
flexible
hardest
hit
hottest
hunters
inclisiran
ipo
key
lowering
meant
medicine
nasdaq
new
novartis
open
passed
poised
pricing
proteins
ras
Language
unset
3
×
Current search:
drug
×
unset
×
medicines
×
sanofi
×
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing